Dicerna Pharmaceuticals (NASDAQ:DRNA) Issues Quarterly Earnings Results

Dicerna Pharmaceuticals (NASDAQ:DRNA) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.15), Fidelity Earnings reports. The business had revenue of $8.04 million during the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 50.30% and a negative net margin of 737.93%.

NASDAQ DRNA traded up $0.09 during trading on Friday, hitting $17.69. The company’s stock had a trading volume of 824,800 shares, compared to its average volume of 465,156. The company has a market cap of $1.17 billion, a PE ratio of -14.74 and a beta of 2.29. Dicerna Pharmaceuticals has a fifty-two week low of $9.31 and a fifty-two week high of $18.39. The business’s 50 day simple moving average is $15.51 and its 200-day simple moving average is $14.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65.

In related news, COO James B. Weissman sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $18.00, for a total transaction of $270,000.00. Following the completion of the sale, the chief operating officer now directly owns 29,704 shares in the company, valued at $534,672. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO John B. Green sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $18.00, for a total value of $225,000.00. The disclosure for this sale can be found here. Insiders sold 42,180 shares of company stock valued at $686,868 over the last 90 days. Company insiders own 21.28% of the company’s stock.

Several brokerages have weighed in on DRNA. Chardan Capital reissued a “buy” rating and issued a $18.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, August 13th. ValuEngine raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday. HC Wainwright set a $22.00 price target on Dicerna Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 26th. Robert W. Baird began coverage on Dicerna Pharmaceuticals in a report on Tuesday, October 29th. They issued an “outperform” rating and a $27.00 price target for the company. Finally, Zacks Investment Research raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $22.50.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: Monthly Dividend Stocks

Earnings History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.